Production (Stage)
Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.00060.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 603.50K | 603.50K | 994.00K | 994.00K | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -18.30K | -18.30K | -17.10K | -17.10K | -- |
| Total Operating Expenses | 1.47M | 1.47M | 1.96M | 1.96M | -- |
| Operating Income | -1.47M | -1.47M | -1.96M | -1.96M | -- |
| Income Before Tax | -2.06M | -2.06M | -2.17M | -2.17M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.06M | -2.06M | -2.17M | -2.17M | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.06M | -2.06M | -2.17M | -2.17M | -- |
| EBIT | -1.47M | -1.47M | -1.96M | -1.96M | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.57 | -0.57 | -1.05 | -1.05 | -14.16 |
| Normalized Basic EPS | -0.36 | -0.36 | -0.66 | -0.66 | -- |
| EPS Diluted | -0.57 | -0.57 | -1.05 | -1.05 | -14.16 |
| Normalized Diluted EPS | -0.36 | -0.36 | -0.66 | -0.66 | -- |
| Average Basic Shares Outstanding | 3.60M | 3.60M | 2.06M | 2.06M | 491.30K |
| Average Diluted Shares Outstanding | 3.60M | 3.60M | 2.06M | 2.06M | 491.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |